Final results of the SMIEC trial in natve patients with hepatitis C: Double therapy (peginterferonalfa2a+ribavirin) vs peginterferon monotherapy in early viral responders and vs triple therapy (peginterferon plus ribavirin plus amantadine) in early non responders